Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes
Authors' conclusion
OGTT reveals early alterations of glucose and insulin metabolism in patients with FPLD2, and should be systematically performed before excluding a diagnosis of prediabetes or diabetes to adapt medical care. Decreased adiponectin is an early marker of the disease. Adiponectin replacement therapy warrants further study in FPLD2.
Study context
- Population
- Adults with familial partial lipodystrophy type 2 (FPLD2) due to the same LMNA variant, and unaffected adult relatives with normal glucose tolerance (NGT)
- Participants
- 102 vs 22
- Exposure
- FPLD2 patients vs unaffected adult relatives with NGT
- FPLD2n = 102
- Unaffected relativesn = 22reference
- Outcome
- Glucose tolerance status in FPLD2
Main finding
As reported in the abstract
- Diabetes or prediabetes
- 65%
- Diabetes
- 41%
- Prediabetes
- 24%
- Age, median (IQR)
- 39.5 years (29.0-50.8)
- BMI, median (IQR)
- 25.5 kg/m² (23.1-29.4)
Observational data: associations, not effects.
Further findings
Insulin sensitivity and secretion (post-load Oral Glucose Tolerance Tests (OGTT))
- Insulin resistance and increased insulin secretion in FPLD2 with NGT; decreased insulin secretion in FPLD2 with diabetes
Impaired glucose tolerance with normal fasting glucose among FPLD2 with prediabetes
- IGT with normal fasting glucose
- 86%
Adiponectin
- Decreased in all subjects with FPLD2 and correlated with insulin sensitivity markers
Original publication
Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes. Diabetes Metab. Published 15 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →